Therapy for hepatitis c virus infection increases survival of patients with pretreatment anemia

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages

  Mohanty, Arpan ^a   Erqou, Sebhat ^a   McGinnis, Kathleen A ^b   Vanasse, Gary ^c   Freiberg, Matthew S ^a   Sherman, Kenneth E ^d   Butt, Adeel A ^e,f  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

Author keywords

Anti HCV Therapy; Complication; Hemoglobin; Side Effect

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; VETERAN;

EID: 84878135138     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.01.023     Document Type: Article

References (33)

1. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
2. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83.
3. Sullivan S.D., Jensen D.M., Bernstein D.E., et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004, 99:1490-1496.
4. Butt A.A., Wang X., Moore C.G. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009, 50:387-392.
5. Backus L.I., Boothroyd D.B., Phillips B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9:509-516.e1.
6. Omland L.H., Jepsen P., Krarup H., et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011, 9:71-78.
7. Jacobson I.M., Davis G.L., El-Serag H., et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8:924-933. quiz e117.
8. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-S244.
9. Sievert W., Dore G.J., McCaughan G.W., et al. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011, 53:1109-1117.
10. Sulkowski M.S., Shiffman M.L., Afdhal N.H., et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010, 139:1602-1611.
11. Nachnani J.S., Rao G.A., Bulchandani D., et al. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol 2010, 89:121-125.
12. Takaki S., Tsubota A., Hosaka T., et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004, 39:668-673.
13. Hiramatsu N., Kurosaki M., Sakamoto N., et al. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. J Gastroenterol 2011, 46:1111-1119.
14. Butt A.A., Justice A.C., Skanderson M., et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56:385-389.
15. Butt A.A., McGinnis K.A., Skanderson M., et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010, 30:240-250.
16. Peck-Radosavljevic M., Boletis J., Besisik F., et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011, 9:242-248.
17. den Elzen W.P., Willems J.M., Westendorp R.G., et al. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus study. CMAJ 2009, 181:151-157.
18. Sullivan P.S., Hanson D.L., Chu S.Y., et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301-308.
19. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818-827.
20. Butt A.A., Khan U.A., McGinnis K.A., et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007, 14:890-896.
21. Butt A.A., Wang X., Fried L.F. HCV infection and the incidence of CKD. Am J Kidney Dis 2011, 57:396-402.
22. McLean E., Cogswell M., Egli I., et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009, 12:444-454.
23. Fultz S.L., Skanderson M., Mole L.A., et al. Development and verification of a "virtual" cohort using the national VA health information system. Med Care 2006, 44:S25-S30.
24. Butt A.A., McGinnis K., Rodriguez-Barradas M.C., et al. HIV infection and the risk of diabetes mellitus. AIDS 2009, 23:1227-1234.
25. Butt A.A., Khan U.A., Shaikh O.S., et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009, 10:25-32.
26. Riva E., Tettamanti M., Mosconi P., et al. Association of mild anemia with hospitalization and mortality in the elderly: the health and anemia population-based study. Haematologica 2009, 94:22-28.
27. da Silveira A.D., Ribeiro R.A., Rossini A.P., et al. Association of anemia with clinical outcomes in stable coronary artery disease. Coron Artery Dis 2008, 19:21-26.
28. Halpern M.T., Zilberberg M.D., Schmier J.K., et al. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc 2006, 4:17.
29. Nomura H., Tanimoto H., Kajiwara E., et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004, 19:1312-1317.
30. Saab S., Hunt D.R., Stone M.A., et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010, 16:748-759.
31. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
32. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
33. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of Boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.